Twist Bioscience Reports 18% Revenue Growth and Net Income Turnaround in Latest Quarter

Twist Bioscience Corporation reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company achieved revenues of $96.1 million, an 18% increase from $81.5 million in the same quarter of the previous year. This growth was primarily driven by increased sales in next-generation sequencing (NGS) tools and synthetic genes. The gross margin also improved to 53.4%, up from 43.3%, reflecting better cost management and increased revenue. The company reported a net income of $20.4 million for the quarter, a notable turnaround from a net loss of $85.6 million in the prior year, largely due to a $48.8 million gain from the sale of its DNA Data Storage business.

In terms of operational changes, Twist Bioscience executed a strategic sale of its DNA Data Storage business to Atlas Data Storage, Inc. on May 2, 2025. This transaction included the transfer of intellectual property and equipment, and it is expected to allow both companies to focus on their core competencies. The sale was part of a broader strategy to enhance operational efficiency and unlock value in their respective markets. The company also reported a decrease in research and development expenses, which fell by 20% to $18.0 million, attributed to reduced personnel costs following the transition of employees to Atlas.

The company’s customer base expanded to approximately 3,562 customers, with a notable increase in the number of genes shipped, rising to about 237,000 in the latest quarter compared to 212,000 a year earlier. This growth in customer engagement and product adoption is indicative of the company's successful multi-channel sales strategy, which includes direct sales and an e-commerce platform. The Americas region accounted for 62% of total revenues, while EMEA contributed 32%, reflecting strong demand across geographic markets.

Twist Bioscience's financial position remains solid, with cash and cash equivalents totaling $201.4 million and short-term investments of $49.4 million as of June 30, 2025. The company anticipates that its current cash reserves will be sufficient to fund operations for at least the next year. Looking ahead, management expressed optimism about future growth, emphasizing the importance of leveraging its proprietary DNA synthesis technology and expanding its product offerings in synthetic biology and biologic drugs.

Overall, the latest quarterly results reflect a significant recovery in financial performance, driven by strategic business decisions and operational efficiencies, positioning Twist Bioscience for continued growth in the synthetic biology sector.